Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255–66.

Article  PubMed  Google Scholar 

Lasta JL, Groto AD, Brandalize APC. Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil. Prev Med Rep. 2023;35:102356.

Article  PubMed  PubMed Central  Google Scholar 

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D. Malignant abnormalities in male BRCA mutation carriers: results from a prospectively screened cohort. JAMA Oncol. 2018;4(6):872–4.

Article  PubMed  PubMed Central  Google Scholar 

Petrucelli N DM, Pal T. : BRCA1- and BRCA2- Associated Hereditary Breast and Ovarian Cancer. In: GeneReviews® edn. Edited by Adam MP FJ, Mirzaa GM, et al. Seattle (WA): University of Washington, Seattle; 2023.

Su Y, Yao Q, Xu Y, Yu C, Zhang J, Wang Q, Li J, Shi D, Yu B, Zeng Y, et al. Characteristics of germline non-BRCA mutation status of high-risk breast cancer patients in china and correlation with high-risk factors and multigene testing suggestions. Front Genet. 2021;12:674094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009;85(4):427–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–9.

Article  CAS  PubMed  Google Scholar 

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.

Article  PubMed  PubMed Central  Google Scholar 

Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71(6):2222–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.

Article  PubMed  PubMed Central  Google Scholar 

Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O’Mara TA, Zhao N, Bolla MK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilcox N, Dumont M, Gonzalez-Neira A, Carvalho S, Joly Beauparlant C, Crotti M, Luccarini C, Soucy P, Dubois S, Nunez-Torres R, et al. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk. Nat Genet. 2023;55(9):1435–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Res. 2022;24(1):2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feliubadalo L, Lopez-Fernandez A, Pineda M, Diez O, Del Valle J, Gutierrez-Enriquez S, Teule A, Gonzalez S, Stjepanovic N, Salinas M, et al. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. Int J Cancer. 2019;145(10):2682–91.

Article  CAS  PubMed  Google Scholar 

Colas C, Golmard L, de Pauw A, Caputo SM, Stoppa-Lyonnet D. “Decoding hereditary breast cancer” benefits and questions from multigene panel testing. Breast. 2019;45:29–35.

Article  PubMed  Google Scholar 

Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R: Landscape of germline mutations in DNA repair genes for breast cancer in latin america: opportunities for PARP-like inhibitors and immunotherapy. Genes (Basel) 2019, 10(10)

Chavarri-Guerra Y, Villarreal-Garza C, Ferrigno AS, Mohar A, Aguilar D, Alvarez-Gomez RM, Gallardo-Alvarado L, Del Toro-Valero A, Quintero-Beulo G, Gutierrez-Delgado F, et al. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer. Salud Publica Mex. 2022;64(1):41–8.

Article  PubMed  Google Scholar 

Perez-Ibave DC, Garza-Rodriguez ML, Noriega-Iriondo MF, Flores-Moreno SM, Gonzalez-Geroniz MI, Espinoza-Velazco A, Castruita-Avila AL, Alcorta-Nunez F, Zayas-Villanueva OA, Gonzalez-Guerrero JF et al: Identification of germline variants in patients with hereditary cancer syndromes in northeast Mexico. Genes (Basel) 2023, 14(2).

Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, Sur S, Ghosh M, Agarwal A, Sarin R, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018;170(1):189–96.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial, High-Risk Assessment: Breast, Ovarian, and Pancreatic [https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf, ]

NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic [https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503]

Tran VT, Nguyen ST, Pham XD, Phan TH, Nguyen VC, Nguyen HT, Nguyen HP, Doan PTT, Le TA, Nguyen BT, et al. Pathogenic variant profile of hereditary cancer syndromes in a vietnamese cohort. Front Oncol. 2021;11:789659.

Article  CAS  PubMed  Google Scholar 

Stradella A, Del Valle J, Rofes P, Feliubadalo L, Grau Garces E, Velasco A, Gonzalez S, Vargas G, Izquierdo A, Campos O, et al. Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? J Med Genet. 2019;56(8):521–5.

Article  CAS  PubMed  Google Scholar 

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78–94.

Article  CAS  PubMed  Google Scholar 

Nastasi C, Mannarino L, D’Incalci M. DNA damage response and immune defense. Int J Mol Sci. 2020;21(20):96.

Article  Google Scholar 

Ye Z, Shi Y, Lees-Miller SP, Tainer JA. Function and molecular mechanism of the DNA damage response in immunity and cancer immunotherapy. Front Immunol. 2021;12:797880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quezada Urban R, Diaz Velasquez CE, Gitler R, Rojo Castillo MP, Sirota Toporek M, Figueroa Morales A, Moreno Garcia O, Garcia Esquivel L, Torres Mejia G, Dean M et al: Comprehensive analysis of germline variants in mexican patients with hereditary breast and ovarian cancer susceptibility. Cancers (Basel) 2018, 10(10).

Chavarri-Guerra YVG, C.; Rodriguez-Olivares, J.L.; Aguilar-y Mendez, D.; Quintero-Beulo, G.; Gutierrez-Delgado, F., Herzog, J.; Gruber, S.: Abstract P6–02–05. Prevalence of non-BRCA germline pathogenic variants in Mexican women with breast cancer referred for genetic cancer risk assessment. In: POSTER SESSION ABSTRACTS| MARCH 01 2023. vol. Cancer Res (2023) 83 (5_Supplement): P6–02–05.: American Association for Cancer Research; 2023.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal. [https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf ]

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists. J Mol Diagn. 2017;19(1):4–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–7.

Article  CAS  PubMed  Google Scholar 

Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, Massouras A. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–80.

Article  CAS